The introduction of nicotinamide as being a nicotine replacement in e-cigarette and smokeless solutions signifies an important regulatory obstacle for the FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is understood to act as a sedative at superior dosages6. The statements produced by Nicotine River, ECBlend, together with o